MPN Landscape Shifts from JAKi Monotherapy to Combining Novel Agents
Key claim: The MPN treatment landscape is moving from JAK inhibitor monotherapy toward combinations with novel agents, marked by FDA approvals of ropeginterferon for PV and pacritinib for thrombocytopenic MF plus pivotal momelotinib data.
Abstract
Expert commentary on the evolving MPN treatment landscape with more than 10 active phase 3 trials combining novel agents with JAK inhibitors. Discusses FDA approvals including ropeginterferon alfa-2b-njft (Besremi) for PV, pacritinib (Vonjo) for thrombocytopenic MF patients, and momelotinib in pivotal phase 3 MOMENTUM trial.
Why this matters
The MPN treatment landscape is moving from JAK inhibitor monotherapy toward combinations with novel agents, marked by FDA approvals of ropeginterferon for PV and pacritinib for thrombocytopenic MF plus pivotal momelotinib data.